v3.26.1
Non-Consolidated Affiliates (Tables)
 6 Months Ended
Jun. 30, 2026
Equity Method Investments and Joint Ventures [Abstract]  
Summary of Equity in Earnings and Distributions of Equity Method Investees
The following table summarizes the cash distributions from our equity method investees, which are recorded within Distributions from equity method investees on the condensed consolidated statements of cash flows (in thousands):

For the Three Months Ended June 30,For the Six Months Ended June 30,
2026202520262025
Distributions from equity method investees
The Legacy SLP Interest$6,365 $62,385 $12,424 $70,722 
Avillion I
— — 13,396 13,396 
Avillion II(1)
1,436 603 28,010 28,528 
Total$7,801 $62,988 $53,830 $112,646 
(1)For the first six months of 2026, amount includes approximately $10.3 million representing our pro rata portion of the $22 million milestone payment Avillion II received from AstraZeneca following the FDA’s approval of a supplemental NDA for Airsupra. For the first six months of 2025, amount includes approximately $27.4 million representing our pro rata portion of the $55 million milestone payment Avillion II received from AstraZeneca following Airsupra meeting the primary endpoint in the Phase 3 clinical trial.